A Target-Disease Network Model of Second-Generation BCR-ABL Inhibitor Action in Ph+ ALL

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) is in part driven by the tyrosine kinase bcr-abl, but imatinib does not produce long-term remission. Therefore, second-generation ABL inhibitors are currently in clinical investigation. Considering different target specificities...

Descripción completa

Detalles Bibliográficos
Autores principales: Rix, Uwe, Colinge, Jacques, Blatt, Katharina, Gridling, Manuela, Remsing Rix, Lily L., Parapatics, Katja, Cerny-Reiterer, Sabine, Burkard, Thomas R., Jäger, Ulrich, Melo, Junia V., Bennett, Keiryn L., Valent, Peter, Superti-Furga, Giulio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795025/
https://www.ncbi.nlm.nih.gov/pubmed/24130846
http://dx.doi.org/10.1371/journal.pone.0077155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795025/
https://www.ncbi.nlm.nih.gov/pubmed/24130846
http://dx.doi.org/10.1371/journal.pone.0077155

Ejemplares similares